Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
about
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patientsAnalysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAARTCYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.The role of transporters in the pharmacokinetics of orally administered drugs.The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
P2860
Q24602072-8F7CB5AA-C5F4-40C8-A3B2-04D2DA8F8A86Q33850686-82AD4715-4560-4B6C-824E-C133A5C5C0EDQ33954823-06CF7DB7-D23C-478F-AA67-D15CF7422283Q34012749-4198B5C3-DDE0-4537-8079-D5C1CFA8051DQ35113316-1EC7F719-9CD9-42A1-A320-0F573D15D0E3Q36701911-E5185210-65DB-4A69-96FA-CD45533F130EQ36901492-64A331EE-5C8A-4846-A543-101E7CE5EA28Q37383940-FB601586-D701-4CA1-8FF5-ACF6031B7BA0Q37537018-20F5208A-BC3C-4CEC-A522-97A4747010F6Q37946959-F211A1CB-580D-48FF-98E3-A2A0583B65B5Q38243832-FBAFFDE7-83F6-43EC-BFAB-9859E93553ADQ38414396-F3AA5E9C-5DE3-4192-AFA5-BECED948F59FQ38691481-8923AE1F-4E57-4654-AA25-973C754E0A69
P2860
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Minimal effect of MDR1 and CYP ...... navir in HIV-infected patients
@ast
Minimal effect of MDR1 and CYP ...... navir in HIV-infected patients
@en
type
label
Minimal effect of MDR1 and CYP ...... navir in HIV-infected patients
@ast
Minimal effect of MDR1 and CYP ...... navir in HIV-infected patients
@en
prefLabel
Minimal effect of MDR1 and CYP ...... navir in HIV-infected patients
@ast
Minimal effect of MDR1 and CYP ...... navir in HIV-infected patients
@en
P2093
P2860
P1476
Minimal effect of MDR1 and CYP ...... navir in HIV-infected patients
@en
P2093
Alain Durand
Bruno Lacarelle
Caroline Solas
Corinne Brunet
Jean-Albert Gastaut
Marie-Pierre Drogoul
Nicolas Simon
Sylvie Quaranta
Véronique Bourgarel-Rey
Véronique Frixon-Marin
P2860
P304
P356
10.1111/J.1365-2125.2007.02903.X
P407
P577
2007-05-22T00:00:00Z